協議正式化了先前宣佈的諒解備忘錄後的初步可行性階段
加拿大不列顛哥倫比亞省温哥華 --（Newsfile Corp. -2026 年 1 月 22 日）- FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0)（以下簡稱 “ 公司” 或 “ FendX”），是一家開發基於技術的解決方案以減少有害病原體傳播的創新表面保護公司，欣然宣佈已於 2026 年 1 月 20 日與美國環保消毒劑製造商 Aquaox LLC（“ Aquaox”）簽署了一份合作協議（以下簡稱 “ 協議”）。
該協議建立在公司與 Aquaox 於 2025 年 11 月 18 日簽署的諒解備忘錄（“ MOU”）的基礎上，並正式化了合作的初步階段。在此階段，雙方將評估技術可行性，並確認可靠配製抗微生物劑的能力。成功完成後，合作可能會推進到最終確定用於產品開發的新型抗微生物劑。
“我們很高興正式化這項合作，這代表了我們與 Aquaox 關係的一個重要下一步，” FendX 首席執行官 Carolyn Myers 博士表示。“這項合作支持我們對新型抗微生物劑的評估，這些劑可能會為未來的產品提供支持。”
“正式化這項協議為我們與 FendX 的合作提供了評估我們抗微生物技術的可行性和性能的框架，” Aquaox 首席執行官 Michel van Schaik 表示。“我們認為這是評估支持開發創新、環保健康和衞生技術解決方案的重要一步。”
該協議包括各方的終止條款，每一方對其自身的費用和支出負責。不能保證根據協議進行的合作工作會超出可行性階段或導致進一步的正式協議、監管批准或商業產品的開發，或者根據諒解備忘錄簽署其他合作或供應協議。推進仍然受到多種因素的影響，包括但不限於技術評估、監管考慮和額外協議的簽署。
關於 FendX Technologies Inc.
FendX 是一家開發創新解決方案以幫助減少日常環境中有害病原體傳播的表面保護公司。利用專有技術，公司正在推進一系列保護性表面塗層，包括 REPELWRAP™薄膜、一種基於液體的納米塗層技術和一種專門的 Foley 導尿管塗層。公司專注於在表面保護領域建立強大的知識產權組合，並致力於識別和推進增強醫療、消費和商業環境中衞生和安全的新技術和材料。瞭解更多信息，請訪問：https://fendxtech.com。
關於 Aquaox LLC.
Aquaox LLC 是一家美國環保消毒劑製造商，專注於次氯酸（“ HOCl”）技術。該公司通過戰略合作伙伴關係成功商業化其基於 HOCl 的化合物，促進了其在醫療、商業和工業領域的收入增長。Aquaox 致力於提供安全、可持續的替代傳統化學消毒劑的方案。
代表公司
“ Carolyn Myers”
Carolyn Myers
首席執行官兼董事
加拿大證券交易所及市場監管機構（根據加拿大證券交易所政策中的定義）對本公告的充分性或準確性不承擔任何責任。
前瞻性聲明
本新聞稿包含某些符合加拿大證券法定義的前瞻性陳述，包括關於：公司的計劃；根據協議提出的合作計劃，包括評估技術可行性和確認可靠配製抗微生物劑的能力；關於合作可能推進至最終確定用於產品開發的新型抗微生物劑的陳述；關於評估可能有助於未來產品供應的新抗微生物劑的陳述；關於 FendX 開發和商業化新型病原體控制產品/衞生解決方案的陳述，包括其益處和擬定目標市場，包括醫療、消費和商業市場；關於擴展公司產品和知識產權組合的陳述；以及正在開發的產品及其相關的任何病原體減少益處。雖然公司相信這些陳述是合理的，但無法保證這些期望會被證明是正確的。這些陳述僅是預測，涉及已知和未知的風險，這些風險可能導致實際結果以及公司的計劃和目標與前瞻性陳述中表達的內容有重大差異，包括：根據協議進行的合作工作可能不會超出可行性階段或導致額外的合作和最終協議、供應協議、監管批准、新型抗微生物劑的開發或商業產品的開發；不利的市場條件；與公司籌集額外資金以完成所有計劃活動（包括根據協議的倡議）相關的風險和不確定性；與每種薄膜、液體配方和導管塗層的研究和開發活動相關的風險，包括成功完成實際性能測試和必要時的放大計劃；公司可能無法擴展其產品管道或執行其業務發展和增長計劃的風險，包括無法開發任何新型抗微生物劑或產品，或無法因與 Aquaox 的合作而開發任何新知識產權；公司產品（包括可能開發的任何新產品）可能無法商業化的風險，如果商業化，可能不會被公眾接受和採用的風險；公司未能如預期或根本未能獲得必要的批准和/或許可的風險；政府監管對公司業務的影響；與公司獲得和保護其知識產權的能力相關的風險；產品候選者僅處於配方/重新配方階段；有限的運營歷史；對合作夥伴、許可方和其他人的依賴；一般經濟和政治條件的影響；以及公司控制之外的其他因素。儘管公司相信前瞻性陳述中反映的期望是合理的，但無法保證未來的結果、活動水平或表現。此外，任何前瞻性陳述僅在作出該陳述的日期有效，除非適用法律要求，公司不承擔更新任何前瞻性陳述的義務，以反映該陳述作出日期之後的事件或情況，或反映意外事件的發生。新因素不時出現，管理層無法預測所有這些因素，也無法提前評估這些因素對公司業務的影響或任何因素或因素組合可能導致實際結果與任何前瞻性陳述中包含的內容有重大差異的程度。讀者應查閲此處列出的所有信息，並應參考公司在 SEDAR+ 上向不列顛哥倫比亞證券委員會提交的風險因素披露。
<img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9526/281311_98d67a71141bfa6c_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9526/281311_98d67a71141bfa6c_logo.jpg"/>
要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/281311
<img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/281311/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/281311/375"/>

FMTOF

FMTO

FendX Technologies Inc. 與 Aquaox LLC 簽署了一項合作協議，以評估開發環保抗菌劑的可行性。該協議正式確立了雙方合作的初始階段，基於之前簽署的諒解備忘錄。兩家公司旨在評估並可能最終確定用於產品開發的新型抗菌劑。此次合作需考慮多種因素，包括技術評估和監管批准。FendX 專注於創新的表面保護解決方案，而 Aquaox 則專注於環保的消毒劑

Agreement formalizes initial feasibility phase following previously announced MOU
<div class="lb-trans">協議正式化了先前宣佈的諒解備忘錄後的初步可行性階段
</div>Vancouver, British Columbia--(Newsfile Corp. - January 22, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0)(the &#34; Company&#34; or &#34; FendX&#34;), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, is pleased to announce it has entered into a collaboration agreement (the &#34; Agreement&#34;) dated January 20, 2026 with Aquaox LLC (&#34; Aquaox&#34;), a U.S. based manufacturer of environmentally responsible disinfectants.
<div class="lb-trans">加拿大不列顛哥倫比亞省温哥華 --（Newsfile Corp. -2026 年 1 月 22 日）- FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0)（以下簡稱 “ 公司” 或 “ FendX”），是一家開發基於技術的解決方案以減少有害病原體傳播的創新表面保護公司，欣然宣佈已於 2026 年 1 月 20 日與美國環保消毒劑製造商 Aquaox LLC（“ Aquaox”）簽署了一份合作協議（以下簡稱 “ 協議”）。
</div>The Agreement builds upon the Memorandum of Understanding (&#34; MOU&#34;) signed between the Company and Aquaox announced November 18, 2025 and formalizes the initial phase of the collaboration. During this phase, the parties will assess technical feasibility and confirm the ability to reliably formulate antimicrobial agents. Upon successful completion, the collaboration may advance toward finalizing novel antimicrobial agents for use in product development.
<div class="lb-trans">該協議建立在公司與 Aquaox 於 2025 年 11 月 18 日簽署的諒解備忘錄（“ MOU”）的基礎上，並正式化了合作的初步階段。在此階段，雙方將評估技術可行性，並確認可靠配製抗微生物劑的能力。成功完成後，合作可能會推進到最終確定用於產品開發的新型抗微生物劑。
</div>&#34;We are pleased to formalize this collaboration, which represents a meaningful next step in our relationship with Aquaox,&#34; said Dr. Carolyn Myers, CEO of FendX. &#34;This collaboration supports our evaluation of new antimicrobial agents that could contribute to future product offerings.&#34;
<div class="lb-trans">“我們很高興正式化這項合作，這代表了我們與 Aquaox 關係的一個重要下一步，” FendX 首席執行官 Carolyn Myers 博士表示。“這項合作支持我們對新型抗微生物劑的評估，這些劑可能會為未來的產品提供支持。”
</div>&#34;Formalizing this agreement provides a framework to evaluate the feasibility and performance of our antimicrobial technology in collaboration with FendX,&#34; said Michel van Schaik, CEO of Aquaox. &#34;We see this as an important step in assessing solutions that support the development of innovative, eco-friendly technologies for health and hygiene.&#34;
<div class="lb-trans">“正式化這項協議為我們與 FendX 的合作提供了評估我們抗微生物技術的可行性和性能的框架，” Aquaox 首席執行官 Michel van Schaik 表示。“我們認為這是評估支持開發創新、環保健康和衞生技術解決方案的重要一步。”
</div>The Agreement includes termination provisions for each party, and each party is responsible for their own costs and expenses. There can be no assurance that the collaboration work pursuant to the Agreement will progress beyond the feasibility phase or result in further definitive agreements, regulatory approvals, or development of commercial products, or that other collaboration or supply agreements will be entered into pursuant to the MOU. Advancement remains subject to several considerations, including but not limited to, technical evaluation, regulatory considerations, and the execution of additional agreements.
<div class="lb-trans">該協議包括各方的終止條款，每一方對其自身的費用和支出負責。不能保證根據協議進行的合作工作會超出可行性階段或導致進一步的正式協議、監管批准或商業產品的開發，或者根據諒解備忘錄簽署其他合作或供應協議。推進仍然受到多種因素的影響，包括但不限於技術評估、監管考慮和額外協議的簽署。
</div>About FendX Technologies Inc.
<div class="lb-trans">關於 FendX Technologies Inc.
</div>FendX is a surface protection company developing innovative solutions to help reduce the spread of harmful pathogens in everyday environments. Leveraging proprietary technologies, the Company is advancing a portfolio of protective surface coatings, including REPELWRAP™ film, a liquid-based nano- coating technology and a specialized Foley catheter coating. The Company is focussed on building a robust intellectual property portfolio in the surface protection space and is committed to identifying and advancing new technologies and materials that enhance hygiene and safety across healthcare, consumer and commercial settings. Learn more at: https://fendxtech.com.
<div class="lb-trans">FendX 是一家開發創新解決方案以幫助減少日常環境中有害病原體傳播的表面保護公司。利用專有技術，公司正在推進一系列保護性表面塗層，包括 REPELWRAP™薄膜、一種基於液體的納米塗層技術和一種專門的 Foley 導尿管塗層。公司專注於在表面保護領域建立強大的知識產權組合，並致力於識別和推進增強醫療、消費和商業環境中衞生和安全的新技術和材料。瞭解更多信息，請訪問：https://fendxtech.com。
</div>About Aquaox LLC.
<div class="lb-trans">關於 Aquaox LLC.
</div>Aquaox LLC is a U.S.-based manufacturer of environmentally responsible disinfectants, specializing in hypochlorous acid (&#34; HOCl&#34;) technologies. The company has successfully commercialized its HOCl-based compounds through strategic partnerships, contributing to their revenue growth across healthcare, commercial, and industrial sectors. Aquaox is committed to delivering safe, sustainable alternatives to conventional chemical disinfectants.
<div class="lb-trans">Aquaox LLC 是一家美國環保消毒劑製造商，專注於次氯酸（“ HOCl”）技術。該公司通過戰略合作伙伴關係成功商業化其基於 HOCl 的化合物，促進了其在醫療、商業和工業領域的收入增長。Aquaox 致力於提供安全、可持續的替代傳統化學消毒劑的方案。
</div>ON BEHALF OF THE COMPANY
<div class="lb-trans">代表公司
</div>&#34; Carolyn Myers&#34;
<div class="lb-trans">“ Carolyn Myers”
</div>Carolyn Myers
<div class="lb-trans">Carolyn Myers
</div>Chief Executive Officer and Director
<div class="lb-trans">首席執行官兼董事
</div>Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
<div class="lb-trans">加拿大證券交易所及市場監管機構（根據加拿大證券交易所政策中的定義）對本公告的充分性或準確性不承擔任何責任。
</div>Forward-Looking Statements
<div class="lb-trans">前瞻性聲明
</div>This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; the proposed collaboration plans pursuant the Agreement including assessing technical feasibility and confirming the ability to reliably formulate antimicrobial agents; statements regarding the collaboration may advance toward finalizing novel antimicrobial agents for use in product development; statements regarding evaluation of new antimicrobial agents that could contribute to future product offerings; statements regarding the development and commercialization of new pathogen-control products/hygiene solutions by FendX, including their benefits and proposed target markets including healthcare, consumer and commercial markets; statements regarding expanding the Company's product and IP portfolio; and products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking statements, including: risks that the collaboration work pursuant to the Agreement will not progress beyond the feasibility phase or result in additional collaboration and definitive agreements, supply agreements, regulatory approvals, development of novel antimicrobial agents or development of commercial products; adverse market conditions; risks and uncertainties associated with the Company's ability to raise additional capital to complete all of its planned activities including initiatives pursuant to the Agreement; risks related to research and development activities for each of the film, liquid formulation and catheter coating, including successful completion of real world performance testing and scale-up initiatives, if required; risks that the Company may not expand its product pipeline or execute its business development and growth plans, including not being able to develop any novel antimicrobial agents or products nor develop any new intellectual property as a result of its collaboration with Aquaox; risks that the Company's products, including any new products that may be developed, may not be commercialized, and if they are commercialized, that they may not be accepted and adopted by the public; the risk that the Company will not obtain necessary approvals and/or clearances as anticipated or at all; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its IP; product candidates only being in formulation/reformulation stages; limited operating history; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's filings with the British Columbia Securities Commission on SEDAR+ at www.sedarplus.ca .
<div class="lb-trans">本新聞稿包含某些符合加拿大證券法定義的前瞻性陳述，包括關於：公司的計劃；根據協議提出的合作計劃，包括評估技術可行性和確認可靠配製抗微生物劑的能力；關於合作可能推進至最終確定用於產品開發的新型抗微生物劑的陳述；關於評估可能有助於未來產品供應的新抗微生物劑的陳述；關於 FendX 開發和商業化新型病原體控制產品/衞生解決方案的陳述，包括其益處和擬定目標市場，包括醫療、消費和商業市場；關於擴展公司產品和知識產權組合的陳述；以及正在開發的產品及其相關的任何病原體減少益處。雖然公司相信這些陳述是合理的，但無法保證這些期望會被證明是正確的。這些陳述僅是預測，涉及已知和未知的風險，這些風險可能導致實際結果以及公司的計劃和目標與前瞻性陳述中表達的內容有重大差異，包括：根據協議進行的合作工作可能不會超出可行性階段或導致額外的合作和最終協議、供應協議、監管批准、新型抗微生物劑的開發或商業產品的開發；不利的市場條件；與公司籌集額外資金以完成所有計劃活動（包括根據協議的倡議）相關的風險和不確定性；與每種薄膜、液體配方和導管塗層的研究和開發活動相關的風險，包括成功完成實際性能測試和必要時的放大計劃；公司可能無法擴展其產品管道或執行其業務發展和增長計劃的風險，包括無法開發任何新型抗微生物劑或產品，或無法因與 Aquaox 的合作而開發任何新知識產權；公司產品（包括可能開發的任何新產品）可能無法商業化的風險，如果商業化，可能不會被公眾接受和採用的風險；公司未能如預期或根本未能獲得必要的批准和/或許可的風險；政府監管對公司業務的影響；與公司獲得和保護其知識產權的能力相關的風險；產品候選者僅處於配方/重新配方階段；有限的運營歷史；對合作夥伴、許可方和其他人的依賴；一般經濟和政治條件的影響；以及公司控制之外的其他因素。儘管公司相信前瞻性陳述中反映的期望是合理的，但無法保證未來的結果、活動水平或表現。此外，任何前瞻性陳述僅在作出該陳述的日期有效，除非適用法律要求，公司不承擔更新任何前瞻性陳述的義務，以反映該陳述作出日期之後的事件或情況，或反映意外事件的發生。新因素不時出現，管理層無法預測所有這些因素，也無法提前評估這些因素對公司業務的影響或任何因素或因素組合可能導致實際結果與任何前瞻性陳述中包含的內容有重大差異的程度。讀者應查閲此處列出的所有信息，並應參考公司在 SEDAR+ 上向不列顛哥倫比亞證券委員會提交的風險因素披露。
</div><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9526/281311_98d67a71141bfa6c_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/9526/281311_98d67a71141bfa6c_logo.jpg"/>
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281311
<div class="lb-trans">要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/281311
</div><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/281311/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/281311/375"/>

FendX 與 Aquaox 簽署合作協議，共同致力於環保抗菌劑的創新 | FDXTF 股票新聞